IRIDEX Corporation (Nasdaq: IRIX) — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; comparative periods ended October 1, 2022. IRIDEX develops, manufactures, and sells ophthalmic laser systems, delivery devices, consumables, and related services for glaucoma and retinal conditions.
Financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $12.85 million | $14.64 million | $39.41 million | $41.78 million |
| Gross profit / margin | $5.62 million / 43.7% | $6.46 million / 44.1% | $16.92 million / 42.9% | $18.70 million / 44.8% |
| Operating loss | $1.69 million | $1.70 million | $6.93 million | $6.13 million |
| Net loss | $1.75 million | $1.77 million | $6.61 million | $6.40 million |
| Net loss per share | $0.11 | $0.11 | $0.41 | $0.40 |
| Net cash used in operations | Not provided for quarter | Not provided for quarter | $5.77 million | $7.93 million |
At September 30, 2023, cash and cash equivalents were $7.98 million, working capital was $17.0 million, total assets were $34.95 million, and stockholders’ equity was $12.06 million. Cash declined $5.94 million from year-end 2022. The company reported no borrowings under its revolving facility and no other debt balance in the presented liabilities. The up-to-$8 million SVB revolving facility was scheduled to mature December 1, 2023; the filing does not establish whether it was extended or replaced.
Changes versus prior periods
- Q3 revenue fell 12.2%; nine-month revenue fell 5.7%. Management attributed the declines mainly to delayed purchase decisions and softer retina demand, plus lower royalties following licensed patent expirations.
- Q3 gross margin decreased 0.4 percentage points; the nine-month margin declined 1.9 points. Management cited lower overhead absorption and a more favorable prior-year product mix.
- Nine-month operating loss widened despite lower total operating expenses, as the gross-profit decline outweighed expense reductions. General and administrative expense rose 10.1%, including personnel-related costs, separation costs, and legal expenses.
- Nine-month operating cash use improved from $7.93 million to $5.77 million, primarily reflecting working-capital movements. Cash nonetheless fell from $13.92 million to $7.98 million.
Business trends, outlook, and risks
- Q3 revenue by product group: Retina $7.87 million, Cyclo G6 $3.04 million, and Other $1.94 million. Retina revenue declined 10.1% year over year in Q3; Cyclo G6 declined 12.1%. For the first nine months, Cyclo G6 revenue was nearly flat year over year, while Retina declined 7.0%.
- Topcon, a 10% shareholder and related party, represented 34% of Q3 revenue and 29% of nine-month revenue. The company’s stated cash sufficiency assessment is for the next 12 months, but it expects continued operating losses and negative operating cash flows and may need additional financing.
- Management cited macroeconomic pressures, including inflation, higher interest rates, currency strength, and customer delays in capital-equipment purchases. It gave no quantified revenue or earnings guidance in the provided filing text.
- A significant reimbursement risk arose after five Medicare Administrative Contractors published a local coverage determination for micro-invasive glaucoma surgery, effective December 24, 2023. IRIDEX believes it may materially limit the U.S. patient types eligible for reimbursement for cyclophotocoagulation; the full business impact cannot yet be estimated. The company and other stakeholders planned to challenge the determination. Management said it would assess and adjust domestic glaucoma operations as appropriate.
- Purchase commitments totaled approximately $23.0 million through fiscal 2025, including $21.4 million due within 12 months. Other notable items include $12.71 million of deferred revenue, substantially related to service obligations and Topcon exclusivity rights, and a $1.1 million capitalized ERP implementation asset.
- Management reported that disclosure controls and procedures were effective at the reasonable-assurance level and that no material changes to internal control over financial reporting occurred during the quarter. The filing describes ordinary-course legal matters as not expected to have a material adverse effect.
Key facts for investors to verify
- Whether the revolving credit facility was renewed, replaced, or otherwise available after its December 1, 2023 scheduled maturity.
- How the Medicare coverage determination is interpreted and applied, and its effects on U.S. Cyclo G6 demand, reimbursement, and glaucoma operations.
- Cash burn, working-capital needs, financing plans, and the company’s ability to meet $21.4 million of near-term purchase commitments.
- Whether retina demand, gross margins, and overall revenue stabilize, and whether royalty declines continue.
- Topcon’s ongoing distribution contribution and concentration, including receivable collection and deferred exclusivity revenue.